National Cancer Institute; Notice of Closed Meeting, 48455-48456 [2013-19109]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 153 / Thursday, August 8, 2013 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meetings
tkelley on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the National
Diabetes and Digestive and Kidney
Diseases Advisory Council.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council.
Date: September 26, 2013.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: To present the Director’s Report
and other scientific presentations.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Closed: 3:45 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D.,
Director, Division of Extramural Activities,
National Institutes of Diabetes And Digestive
And Kidney Diseases, 6707 Democracy Blvd.
Room 715, Msc 5452, Bethesda, MD 20892,
(301) 594–8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council, Kidney, Urologic and Hematologic
Diseases Subcommittee.
Date: September 26, 2013.
Open: 1:00 p.m. to 3:00 p.m.
Agenda: To review the Division’s scientific
and planning activities.
Place: National Institutes of Health,
Building 31, Conference Room 7, 31 Center
Drive, Bethesda, MD 20892.
Closed: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Mar<15>2010
16:55 Aug 07, 2013
Jkt 229001
Place: National Institutes of Health,
Building 31, Conference Room 7, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D.,
Director, Division of Extramural Activities,
National Institutes of Diabetes and Digestive
And Kidney Diseases, 6707 Democracy Blvd.
Room 715, Msc 5452, Bethesda, Md 20892,
(301) 594–8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council, Digestive Diseases and Nutrition
Subcommittee.
Date: September 26, 2013.
Open: 1:00 p.m. to 2:15 p.m.
Agenda: To review the Division’s scientific
and planning activities.
Place: National Institutes of Health,
Building 31, Conference Room 6, 31 Center
Drive, Bethesda, MD 20892.
Closed: 2:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 6, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D.,
Director, Division Of Extramural Activities,
National Institutes of Diabetes and Digestive
and Kidney Diseases, 6707 Democracy Blvd.
Room 715, MSC 5452, Bethesda, MD 20892,
(301) 594–8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council Diabetes, Endocrinology and
Metabolic Diseases Subcommittee.
Date: September 26, 2013.
Open: 1:00 p.m. to 2:15 p.m.
Agenda: To review the Division’s scientific
and planning activities.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Closed: 2:15 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D.,
Director, Division of Extramural Activities,
National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd.
Room 715, MSC 5452, Bethesda, MD 20892,
(301) 594–8843, stanfibr@niddk.nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
48455
business or professional affiliation of the
interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
www.niddk.nih.gov/fund/divisions/DEA/
Council/coundesc.htm., where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 2, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–19110 Filed 8–7–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Advisory Board.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Date: September 10, 2013.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892, (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 9609
E:\FR\FM\08AUN1.SGM
08AUN1
48456
Federal Register / Vol. 78, No. 153 / Thursday, August 8, 2013 / Notices
Medical Center Drive, Room 7W–444,
Bethesda, MD 20892, (240) 276–6340.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 2, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–19109 Filed 8–7–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Biomarkers for AKI
and CKD.
Date: September 25, 2013.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: D. G. Patel, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 756, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452-5452, (301) 594–
7682, pateldg@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Pharmacogenomics
or Metformin.
Date: September 27, 2013.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892-5452,
(Telephone Conference Call).
Contact Person: D. G. Patel, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 756, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Last name
First name
Waters ...........................................................................
Partyka ...........................................................................
Hastings, Jr. ...................................................................
Scarangello ....................................................................
Dated: August 2, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–19111 Filed 8–7–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Notice of Cancellation of Customs
Broker Licenses Due to Death of the
License Holder
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Customs broker license
cancellation due to death of the broker.
AGENCY:
Notice is hereby given that
the customs broker licenses of certain
brokers have been cancelled without
prejudice due to the death of the license
holders.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that, pursuant to section
641 of the Tariff Act of 1930, as
amended (19 U.S.C. 1641) and section
111.51(a) of title 19 of the Code of
Federal Regulations (19 CFR 111.51(a)),
the following customs broker licenses
and any and all associated permits have
been cancelled without prejudice due to
death of the broker.
SUMMARY:
Owen .......................................................
Leo ...........................................................
Daniel ......................................................
Peter ........................................................
Dated: August 2, 2013.
Richard F. DiNucci,
Deputy Assistant Commissioner, Office of
International Trade.
[FR Doc. 2013–19128 Filed 8–7–13; 8:45 am]
BILLING CODE 9111–14–P
License No.
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Notice of Cancellation of Customs
Broker Licenses
U.S. Customs and Border
Protection, Department of Homeland
Security.
AGENCY:
tkelley on DSK3SPTVN1PROD with NOTICES
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Customs broker license
cancellations.
ACTION:
VerDate Mar<15>2010
16:55 Aug 07, 2013
Jkt 229001
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
02371
09556
05745
06420
Port of issuance
Charlotte.
Chicago.
Laredo.
Los Angeles.
Notice is hereby given that
the customs broker licenses and any and
all associated permits of certain customs
brokers are being cancelled without
prejudice.
SUMMARY:
SUPPLEMENTARY INFORMATION:
Notice is hereby given that, pursuant
to section 641 of the Tariff Act of 1930,
as amended (19 U.S.C. 1641), and
section 111.51(a) of title 19 of the Code
of Federal Regulations (19 CFR
111.51(a)), the following customs broker
licenses are cancelled without
prejudice.
E:\FR\FM\08AUN1.SGM
08AUN1
]]>Agencies
[Federal Register Volume 78, Number 153 (Thursday, August 8, 2013)]
[Notices]
[Pages 48455-48456]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-19109]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Cancer Advisory Board.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Date: September 10, 2013.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD
20892, (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Executive Secretary,
National Cancer Institute, National Institutes of Health, 9609
[[Page 48456]]
Medical Center Drive, Room 7W-444, Bethesda, MD 20892, (240) 276-
6340.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: August 2, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-19109 Filed 8-7-13; 8:45 am]
BILLING CODE 4140-01-P
